Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Interim Management Statement

13 Nov 2012 07:00

RNS Number : 9244Q
Persimmon PLC
13 November 2012
 



INTERIM MANAGEMENT STATEMENT

TUESDAY 13 NOVEMBER 2012

 

 

 

Persimmon plc today releases its Interim Management Statement which covers the period from 1 July 2012 to 12 November 2012. We are pleased to confirm current trading is in line with our expectations.

 

As reported at our half year results on 21 August 2012 weekly private sales rates were c. 5% ahead of the prior year through the traditionally slower summer weeks. On entering the autumn selling season from the second week of September we experienced the usual seasonal pick-up in sales. Notwithstanding the tougher comparatives resulting from the stronger autumn season last year, our weekly private sales rate is similarly c. 4% ahead year on year. Visitor levels to our sites have been c. 6% ahead of last year from the start of the autumn season and cancellation rates continue to run at historically low levels at c. 20%.

 

The cost of mortgage loans has recently reduced slightly as lenders access the Government's Funding for Lending Scheme and pass the lower funding costs through to customers. The take-up of the Government backed 5% deposit NewBuy mortgage product is as a result gradually improving. To date we have supported over 450 customers to purchase a home with a NewBuy mortgage.

 

We have already opened 50 of the c. 60 new sites we scheduled for the second half of the current year. We anticipate our active site numbers will remain stable at c. 375 sites for the remainder of 2012.

 

In February, we launched our new Long Term Strategy designed to grow Persimmon into a larger, stronger business over the next decade, whilst delivering a substantial capital return to shareholders. As explained at that time, a continued focus on improving profitability and free cash generation are important components of this strategy. Achieving the best selling price for our new homes is a key element in delivering these objectives. We anticipate an improvement in our average selling price to c. £172,000 for the full year, an increase of c. 5% over the prior year (2011: £163,999) due to change in sales mix which is in line with our first half performance. Prices have remained stable through the period. We are fully sold up for the current year and have c. £508 million forward sales reserved beyond 2012, a c. 5% increase on the comparable prior year position (2011: £484 million).

 

We have previously indicated that we anticipate the Group returning to underlying operating margins within the range of 15% to 17% in the medium term. We are confident that the second half of 2012 will demonstrate further good progress along that path, building upon the improvement to 12.2% secured in the first six months of the year (from 9.0% in H1 2011). Return on capital employed will continue to increase, supported by our tight control over development costs and a healthy level of site replacement, to reach c. 12% for the current year (2011: 8.3%). We expect further improvement to come in the future.

 

A critical part of our strategy is the continued investment in new land to support the growth of Persimmon in the future. We have acquired over 5,500 plots since 1 July, including c. 1,600 plots in the South East with the acquisition of Hillreed Homes on 5 October 2012, adding to the 5,779 new plots acquired in the first half of 2012. Hillreed, a strong brand with a reputation for high quality, is complementary to our Charles Church business, and has strong strategic land holdings in Kent and Sussex. The promotion and conversion of strategic land is a key element of our land replacement activities and since 1 July c. 32% of our acquired plots have been successfully converted from our strategic landbank. We have delivered additional profit and cash returns on legally completing new homes from these sites over many years.

 

We anticipate we will be holding an increased level of cash at the close of the year (30 June 2012: £135.2 million) resulting from the strong free cash generated by our operations.

 

The UK housing market continues to be challenging and mortgage availability remains the key constraint. However, with the adoption of our new Long Term Strategy at the start of the year we remain confident of the future successful growth of Persimmon and the delivery of significant value to our shareholders over the coming years.

 

We will give a further update on progress and trading following the year end on Tuesday 8 January 2013.

 

Mike Farley and Mike Killoran will host a conference call with analysts at 9.00 a.m. today. To participate please dial +44 (0)20 3003 2666. The password is "Persimmon".

 

For further information, please contact:

 

 

Simon Rigby

Kevin Smith

 

Citigate Dewe Rogerson

 

Mike Farley, Group Chief Executive

Mike Killoran, Group Finance Director

 

Persimmon plc

 

Tel: +44 (0) 20 7638 9571 on the day

Tel: +44 (0) 20 7638 9571

Tel: +44 (0) 1904 642199 thereafter

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUURNRURAAAAA
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.